Ariƫns, L. (2020). Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-weeks results from the Dutch BioDay registry [Data set]. Mendeley. https://doi.org/10.17632/J7MXZZBHC5.1